Abstract
This is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a significant health concern and a lack of knowledge exists about the cost-effectiveness (the balance of a treatment’s cost and its effectiveness) of new treatments. This research assessed the cost-effectiveness of a new medication named faricimab, using a mathematical model that simulated the progression of DMO and its treatment over 25 years. The model compared faricimab against relevant therapeutic alternatives for DMO in the UK, including ranibizumab, aflibercept, and bevacizumab. The research discovered that faricimab could offer improved vision results and be cost saving or cost-effective. It also suggested that faricimab could lessen the strain on healthcare services due to its less frequent dosing schedule. Overall, such findings suggest that faricimab is a promising new treatment option for DMO that could benefit patients and the healthcare system. This could have implications for future treatment guidelines and the management of DMO in clinical practice.
Avoid common mistakes on your manuscript.
Summary of Research
This is a summary of the original article: “Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis” [1].
Data Availability
All data used for the cost-effectiveness model are provided in the original article or are publicly available as indicated by citations. The cost-effectiveness model was developed in Microsoft Excel 365 (Microsoft Corporation). Additional information about model programming is available from the corresponding author upon request.
Reference
Bührer C, Paling T, Gale R, Paulo T, Bagijn M. Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): a UK analysis. PharmacoEcon Open. 2024;8(3):445–57. https://doi.org/10.1007/s41669-023-00465-4.
Acknowledgements
Medical Writing/Editorial Assistance
This summary was developed by Steve Winter, Keith Evans, and Simon Rowlands of inScience Communications, a part of Springer Healthcare/Springer Nature Group, including the use of currently available AI platforms (April 2024). The output generated by such AI systems has undergone human intervention by professional inScience Communications staff for accuracy and quality assurance purposes. Medical writing support was funded by F. Hoffmann-La Roche Limited, Basel, Switzerland.
Funding
This analysis and this summary of the study results were funded by F. Hoffmann-La Roche Limited, Basel, Switzerland. The sponsor also funded the journal’s Rapid Service Fee.
Author information
Authors and Affiliations
Contributions
Christian Bührer, Thomas Paling, Richard Gale, Tatiana Paulo, and Marloes Bagijn all agreed to the development and submission of this Summary of Research article and approved the final version for publication.
Corresponding author
Ethics declarations
Conflict of Interest
Please see the original article for full author disclosures.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for ethics relating to the original study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Bührer, C., Paling, T., Gale, R. et al. Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis. Ophthalmol Ther (2024). https://doi.org/10.1007/s40123-024-00979-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40123-024-00979-y